WebJul 8, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. WebCK-136. Reldesemtiv. Publications. Scientific Events. We’re advancing muscle biology-driven treatments for diseases characterized by compromised muscle function, muscle weakness, and fatigue. ... Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors.
Cytokinetics Omecamtiv Mecarbil Heart Failure
WebOct 21, 2024 · SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to the discovery and optimization of CK-3828136 (CK-136 ... WebDec 7, 2024 · CK-136 is a cardiac troponin activator, discovered under a previous joint research program with Amgen Inc. (Amgen), in development for the potential treatment … dewey township wisconsin
Cytokinetics Reports Fourth Quarter 2024 Financial Results
Webck-136 Cytokinetics is developing CK-136, an investigational, novel, selective, oral, small molecule cardiac troponin activator, as a potential treatment of patients with heart failure with reduced ejection fraction (HFrEF) and other types of heart failure, such … Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator … Main Telephone: (650) 624-3000. Investor Relations – [email protected]. … Cytokinetics is dedicated to the communities it serves and furthering … Our Mission. We are developing potential medicines to improve the healthspan of … Cytokinetics is developing omecamtiv mecarbil, a novel, selective cardiac … Cytokinetics is a leader in muscle biology with over 50 clinical trials. Careers; … Cytokinetics is dedicated to the communities it serves and furthering … We have robust pipeline of small molecule muscle activators and inhibitors, … Scientific Events. March 4-6, 2024 ACC.23 Annual Session & Expo of the American … Cytokinetics is a leader in muscle biology research. Efficacy of omecamtiv … WebOct 29, 2024 · SOUTH SAN FRANCISCO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data relating to the discovery and optimization of CK ... WebNov 15, 2024 · In preclinical models, CK-136 increases myocardial contractility by binding to cardiac troponin through an allosteric mechanism that sensitizes the cardiac sarcomere … dewey township burnett county wisconsin